|
1
|
Chambers SK, Dunn J, Occhipinti S, Hughes
S, Baade P, Sinclair S, Aitken J, Youl P and O'Connell DL: A
systematic review of the impact of stigma and nihilism on lung
cancer outcomes. BMC Cancer. 12:1842012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee PN, Forey BA and Coombs KJ: Systematic
review with meta-analysis of the epidemiological evidence in the
1900s relating smoking to lung cancer. BMC Cancer. 12:3852012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gilham C, Rake C, Burdett G, Nicholson AG,
Davison L, Franchini A, Carpenter J, Hodgson J, Darnton A and Peto
J: Pleural mesothelioma and lung cancer risks in relation to
occupational history and asbestos lung burden. Occup Environ Med.
73:290–299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Larsen JE and Minna JD: Molecular biology
of lung cancer: Clinical implications. Clin Chest Med. 32:703–740.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen W, Li Z, Bai L and Lin Y: NF-kappaB
in lung cancer, a carcinogenesis mediator and a prevention and
therapy target. Front Biosci. 1:1172–1185. 2011. View Article : Google Scholar
|
|
6
|
Zhang B-Y, Wang Y-M, Gong H, Zhao H, Lv
X-Y, Yuan GH and Han SR: Isorhamnetin flavonoid synergistically
enhances the anticancer activity and apoptosis induction by
cis-platin and carboplatin in non-small cell lung carcinoma
(NSCLC). Int J Clin Exp Pathol. 8:25–37. 2015.PubMed/NCBI
|
|
7
|
Ueno NT and Mamounas EP: Neoadjuvant
nab-paclitaxel in the treatment of breast cancer. Breast Cancer Res
Treat. 156:427–440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zou H, Li L, Garcia Carcedo I, Xu ZP,
Monteiro M and Gu W: Synergistic inhibition of colon cancer cell
growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual
inhibitor BEZ235 through apoptosis. Int J Nanomed. 11:1947–1958.
2016.
|
|
9
|
Chen QY, Jiao DM, Wu YQ, Chen J, Wang J,
Tang XL, Mou H, Hu HZ, Song J, Yan J, et al: MiR-206 inhibits
HGF-induced epithelial-mesenchymal transition and angiogenesis in
non-small cell lung cancer via c-Met/PI3k/Akt/mTOR pathway.
Oncotarget. 7:18247–18261. 2016.PubMed/NCBI
|
|
10
|
Mateen S, Raina K and Agarwal R:
Chemopreventive and anti-cancer efficacy of silibinin against
growth and progression of lung cancer. Nutr Cancer. 65 Suppl
1:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin S, Deng Y, Hao J-W, Li Y, Liu B, Yu Y,
Shi FD and Zhou QH: NK cell phenotypic modulation in lung cancer
environment. PLoS One. 9:e1099762014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Samanta D, Kaufman J, Carbone DP and Datta
PK: Long-term smoking mediated down-regulation of Smad3 induces
resistance to carboplatin in non-small cell lung cancer. Neoplasia.
14:644–655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma T, Fuld AD, Rigas JR, Hagey AE, Gordon
GB, Dmitrovsky E and Dragnev KH: A phase I trial and in vitro
studies combining ABT-751 with carboplatin in previously treated
non-small cell lung cancer patients. Chemotherapy. 58:321–329.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Khongkow P, Gomes AR, Gong C, Man EPS,
Tsang JWH, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US and
Lam EW: Paclitaxel targets FOXM1 to regulate KIF20A in mitotic
catastrophe and breast cancer paclitaxel resistance. Oncogene.
35:990–1002. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Q, Si S, Schoen S, Chen J, Jin XB
and Wu G: Suppression of autophagy enhances preferential toxicity
of paclitaxel to folliculin-deficient renal cancer cells. J Exp
Clin Cancer Res. 32:992013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang C, Lan T, Hou J, Li J, Fang R, Yang
Z, Zhang M, Liu J and Liu B: NOX4 promotes non-small cell lung
cancer cell proliferation and metastasis through positive feedback
regulation of PI3K/Akt signaling. Oncotarget. 5:4392–405. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng H, Zou Y, Ross JS, Wang K, Liu X,
Halmos B, Ali SM, Liu H, Verma A and Montagna C: RICTOR
amplification defines a novel subset of patients with lung cancer
who may benefit from treatment with mTORC1/2 inhibitors. Cancer
Discov. 5:1262–1270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu Q, Qin SK, Teng FM, Chen CJ and Wang R:
Lobaplatin arrests cell cycle progression in human hepatocellular
carcinoma cells. J Hematol Oncol. 3:432010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Owonikoko TK, Ramalingam SS, Kanterewicz
B, Balius TE, Belani CP and Hershberger PA: Vorinostat increases
carboplatin and paclitaxel activity in non-small-cell lung cancer
cells. Int J Cancer. 126:743–755. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang X, Zheng D, Hu P, Zeng Z, Li M,
Tucker L, Monahan R, Resnick MB, Liu M and Ramratnam B: Glycogen
synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the
β-Catenin/TCF/LEF 1 pathway in gastric cancer cells. Nucleic Acids
Res. 42:2988–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
